MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00228-022-03391-2

Медицинская библиотека · European journal of clinical pharmacology · 2022

The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study.

Elshafei Mohamed Nabil, Imam Yahia, Alsaud Arwa Ebrahim, Chandra Prem, Parray Aijaz, Abdelmoneim Mohamed S, Obeidat Khaldun, Saeid Razan, Ali Mohammad, Ayadathil Raheem, Mohamed Mouhand F H, Abdallah Ibtihal M, Mohammed Shaban, Akhtar Naveed, Danjuma Mohammed Ibn-Masoud

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.

METHODS

A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).

RESULTS

Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%; P = 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27; P = 0.047). No incidence of GIT bleeding observed throughout the study.

CONCLUSION

A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.

Для цитирования: Elshafei Mohamed Nabil, Imam Yahia, Alsaud Arwa Ebrahim, Chandra Prem, Parray Aijaz, Abdelmoneim Mohamed S, Obeidat Khaldun, Saeid Razan, Ali Mohammad, Ayadathil Raheem, Mohamed Mouhand F H, Abdallah Ibtihal M, Mohammed Shaban, Akhtar Naveed, Danjuma Mohammed Ibn-Masoud. The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study.. European journal of clinical pharmacology. 2022. DOI: 10.1007/s00228-022-03391-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.